The alternating current polarographic behavior and determination of lansoprazole and omeprazole in dosage forms and biological fluids

Add time:07/21/2019    Source:sciencedirect.com

The alternating current (ACt) polarographic behavior of lansoprazole (LNS) and omeprazole (OMP) was studied in Britton Robinson buffers (BRb) over the pH range 4.1–11.5. In BRb of pH 9.6 and 10.5, well-defined ACt peaks were obtained for both LNS and OMP, respectively. The current–concentration plots were rectilinear over the ranges of 0.4–20 µg mL− 1 and 0.2–10 µg mL− 1 for LNS and OMP respectively. The minimum detection limits (S/N = 2) were 0.02 µg mL− 1 (5.4 × 10− 8 M) and 0.01 µg mL− 1 (2.9 × 10− 8 M) for LNS and OMP, respectively. The proposed method was successfully applied to the analysis of the two drugs in their commercial capsules. The average percent recoveries were favorably compared to those obtained by reference methods. Co-administered drugs such as naproxen and methotrexate did not interfere with the proposed method. The proposed method was further extended to the in-vitro determination of the lansoprazole in spiked plasma, the percentage recoveries was 98.47 ± 1.29 (n = 4). The pathway for the electrode reaction for both drugs involved reduction of the sulphonyl group into the corresponding thiol group at the Dropping Mercury Electrode. The advantages of the method were time saving and more sensitive than the other published voltammetric method. Yet The present study is the first report on the use of alterating current polarography (ACt) in this respect.

We also recommend Trading Suppliers and Manufacturers of 5-HYDROXY LANSOPRAZOLE (cas 131926-98-2). Pls Click Website Link as below: cas 131926-98-2 suppliers

Prev:Determination of lansoprazole and two of its metabolites by liquid–liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity
Next:Lansoprazole increases testosterone metabolism and clearance in male Sprague-Dawley rats: implications for leydig cell carcinogenesis)